Last reviewed 2026-04-19 · How we verify

HNC664 capsules FED

Guangzhou Henovcom Bioscience Co. Ltd. · Phase 1 active Small molecule

HNC664 capsules FED is a Small molecule drug developed by Guangzhou Henovcom Bioscience Co. Ltd.. It is currently in Phase 1 development. Also known as: HNC664 capsules.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HNC664 capsules FED
Also known as	HNC664 capsules
Sponsor	Guangzhou Henovcom Bioscience Co. Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HNC664 capsules FED CI brief — competitive landscape report
HNC664 capsules FED updates RSS · CI watch RSS
Guangzhou Henovcom Bioscience Co. Ltd. portfolio CI

Frequently asked questions about HNC664 capsules FED

What is HNC664 capsules FED?

HNC664 capsules FED is a Small molecule drug developed by Guangzhou Henovcom Bioscience Co. Ltd..

Who makes HNC664 capsules FED?

HNC664 capsules FED is developed by Guangzhou Henovcom Bioscience Co. Ltd. (see full Guangzhou Henovcom Bioscience Co. Ltd. pipeline at /company/guangzhou-henovcom-bioscience-co-ltd).

Is HNC664 capsules FED also known as anything else?

HNC664 capsules FED is also known as HNC664 capsules.

What development phase is HNC664 capsules FED in?

HNC664 capsules FED is in Phase 1.

Manufacturer: Guangzhou Henovcom Bioscience Co. Ltd. — full pipeline
Also known as: HNC664 capsules

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing